Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome

Journal of the Renin-angiotensin-aldosterone System : JRAAS
Haralampos J MilionisKostas C Siamopoulos

Abstract

To evaluate the influence of clinical, biochemical and genetic markers on the response to antihypertensive treatment in patients with essential hypertension and the metabolic syndrome (MetS). Measurements of anthropometric indices, blood pressure (BP), and metabolic parameters were obtained from the medical records of 132 (77 women) newly diagnosed, untreated hypertensive patients. Renin-angiotensin-aldosterone system (RAAS) genes polymorphisms (including ACE I/D, angiotensinogen M235T, angiotensin II type 1 receptor [AT1-receptor] A1166C) were determined. Response to treatment was defined as BP less than 140/90 mmHg. Patients with MetS (n=60) had higher systolic BP and pulse pressure and a more atherogenic lipid profile than patients without MetS. The frequencies of the ACE and the AT1-receptor gene polymorphisms were similar between patients with and without MetS. Response to treatment was positively associated with pulse pressure, and the presence of the C allele as well as the AC genotype of the AT1-receptor gene and inversely with age after adjustment for confounding factors. RAAS genes distribution does not differ between hypertensive patients with and without the MetS. Higher baseline pulse pressure levels, the presence ...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Nov 1, 1993·American Journal of Hypertension·R R WilliamsE H Ludwig
Apr 1, 1997·Metabolism: Clinical and Experimental·K C Chiu, J E McCarthy
Nov 30, 2000·Clinical Chemistry and Laboratory Medicine : CCLM·B Baudin
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Oct 11, 2001·Journal of Hypertension·L KurlandUNKNOWN Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial
Mar 1, 2003·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·G H GoossensM A van Baak
Apr 10, 2004·Current Opinion in Nephrology and Hypertension·Pasquale Strazzullo, Ferruccio Galletti
Nov 2, 2004·The New England Journal of Medicine·Anthony H BarnettUNKNOWN Diabetics Exposed to Telmisartan and Enalapril Study Group
Apr 20, 2005·Lancet·Robert H EckelPaul Z Zimmet
Sep 27, 2005·Lancet·K George M M AlbertiUNKNOWN IDF Epidemiology Task Force Consensus Group

❮ Previous
Next ❯

Citations

Apr 8, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Maria M Morales-Suárez-VarelaF J Chaves
Aug 12, 2009·Pharmacogenomics·Donna K Arnett, Steven A Claas
Dec 12, 2012·Annals of Human Biology·Lenka LuptákováPavel Blažíček
Jan 3, 2012·Metabolism: Clinical and Experimental·Bo XiJie Mi
Sep 8, 2010·European Journal of Internal Medicine·Lucia Maria ProcopciucDumitru Zdrenghea
Jul 29, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Clayton F MoraesOtávio T Nóbrega
May 16, 2017·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Sandro S AlmeidaRonaldo C Araújo
Feb 19, 2011·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Szilvia FiatalRóza Adány
Apr 22, 2017·Indian Journal of Clinical Biochemistry : IJCB·G K BhattiB Singh
Jul 9, 2014·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Farzad HeidariSuhaili Abu Bakar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.